Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in two major investor events in May 2025. The company will present at The Citizens Life Sciences Conference in New York on May 8, 2025, at 1:30 PM ET, and at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025, at 11:30 AM ET. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione a due importanti eventi per investitori a maggio 2025. La società presenterà al The Citizens Life Sciences Conference a New York l'8 maggio 2025 alle 13:30 ET, e al H.C. Wainwright 3rd Annual BioConnect Investor Conference presso il NASDAQ il 20 maggio 2025 alle 11:30 ET. Entrambe le presentazioni saranno disponibili in webcast e archiviate per 90 giorni nella pagina Eventi di Compass.
Compass Therapeutics (NASDAQ: CMPX), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar terapias contra el cáncer basadas en anticuerpos, ha anunciado su participación en dos importantes eventos para inversores en mayo de 2025. La compañía presentará en The Citizens Life Sciences Conference en Nueva York el 8 de mayo de 2025 a la 1:30 PM ET, y en el H.C. Wainwright 3rd Annual BioConnect Investor Conference en NASDAQ el 20 de mayo de 2025 a las 11:30 AM ET. Ambas presentaciones estarán disponibles vía webcast y archivadas durante 90 días en la página de eventos de Compass.
Compass Therapeutics (NASDAQ: CMPX)는 항체 기반 암 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 2025년 5월에 개최되는 두 개의 주요 투자자 행사에 참여한다고 발표했습니다. 회사는 2025년 5월 8일 오후 1시 30분(동부시간)에 뉴욕에서 열리는 The Citizens Life Sciences Conference에서 발표하며, 2025년 5월 20일 오전 11시 30분(동부시간)에는 NASDAQ에서 열리는 H.C. Wainwright 3rd Annual BioConnect Investor Conference에서 발표할 예정입니다. 두 발표 모두 웹캐스트로 제공되며, Compass 이벤트 페이지에서 90일간 아카이브로 이용할 수 있습니다.
Compass Therapeutics (NASDAQ : CMPX), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements anticancéreux à base d'anticorps, a annoncé sa participation à deux événements majeurs pour investisseurs en mai 2025. L'entreprise présentera lors de The Citizens Life Sciences Conference à New York le 8 mai 2025 à 13h30 ET, ainsi qu'au H.C. Wainwright 3rd Annual BioConnect Investor Conference au NASDAQ le 20 mai 2025 à 11h30 ET. Les deux présentations seront disponibles en webcast et archivées pendant 90 jours sur la page Événements de Compass.
Compass Therapeutics (NASDAQ: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Antikörper-basierten Krebstherapeutika spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenveranstaltungen im Mai 2025 angekündigt. Das Unternehmen wird am The Citizens Life Sciences Conference in New York am 8. Mai 2025 um 13:30 Uhr ET und am H.C. Wainwright 3rd Annual BioConnect Investor Conference am NASDAQ am 20. Mai 2025 um 11:30 Uhr ET präsentieren. Beide Präsentationen werden per Webcast verfügbar sein und für 90 Tage auf der Veranstaltungsseite von Compass archiviert.
- None.
- None.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
What investor conferences will CMPX attend in May 2025?
When is Compass Therapeutics (CMPX) presenting at the Citizens Life Sciences Conference?
How long will CMPX's conference presentations be available for replay?
What type of company is Compass Therapeutics (CMPX)?
